Bastide Le Confort Médical (BLC) Q2 2026 TU earnings summary

Executive summary

• First-half 2025-2026 revenue rose 8.0% year-over-year to €260.4 million, with organic growth at 8.2%.

• Home healthcare services delivered strong organic growth of 7.9%, despite a 5% price cut in the sleep apnea segment since April 2025.

Financial highlights

• First-quarter revenue was €126.3 million, up 8.0% year-over-year; second-quarter revenue reached €134.1 million, also up 8.0%.

• Homecare business revenue totaled €101.4 million, up 6.5% year-over-year.

• Healthcare institutions business revenue grew 12.2% to €46.7 million, driven by profitable rental activities and new contracts.

• Respiratory business revenue increased 11.0% organically to €85.9 million, with international organic growth at 21%.

• Nutrition-Perfusion-Diabetes-Stomatherapy revenue rose 7.2% to €73.0 million, led by double-digit growth in Diabetes and recovery in Stomatherapy.

Outlook and guidance

• Annual revenue target for 2025-2026 is at least €510 million, with an operating margin around 9.0%.

• Net debt/EBITDA is expected to fall below 3 by December 31, 2025, supported by asset disposals and disciplined financial management.